Valion Bio, Inc. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 5/100
What the filing says
CEO Michael K. Handley and CFO Lisa Wolf certified the June 30, 2026 quarterly report on August 14, 2026, affirming accuracy of financial statements and effectiveness of internal controls per Sarbanes-Oxley requirements. No material weaknesses, significant deficiencies, or fraud disclosed. These are routine periodic certifications required by SEC rules 13a-14(a), 15d-14(a), and 18 U.S.C. § 1350.
Why this rating
Boilerplate SOX certification exhibits; standard quarterly disclosure. No operational, financial, or strategic content disclosed. Routine compliance filing.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.